ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Serum response factor as a prognostic indicator of angiogenesis and early recurrence in Glioblastoma: a retrospective immunohistochemical study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the clinical significance of serum response factor (SRF) expression and its association with microvascular density (MVD) and postoperative recurrence in glioblastoma (GBM) patients.
methodsThis retrospective study included 92 patients with pathologically confirmed GBM who underwent surgical resection between July 2021 and July 2023. Tumor and adjacent normal brain tissues were analyzed via immunohistochemistry to assess SRF expression and CD105-labeled MVD. Spearman's correlation was used to determine the association between SRF and MVD. Postoperative recurrence was monitored for 12 months, and multivariate logistic regression was conducted to identify independent predictors of recurrence.
resultsSRF was positively expressed in 56.5% of tumor samples, significantly higher than in adjacent normal tissue (2.2%, P < 0.001). SRF-positive tumors demonstrated increased MVD compared to SRF-negative tumors (86.79 ± 14.12 vs. 70.58 ± 8.77 vessels/field, P < 0.05). A strong positive correlation was found between SRF expression and MVD (r = 0.749, P < 0.05). At 1-year follow-up, 24 patients (26.1%) experienced recurrence. SRF positivity, tumor diameter ≥ 5 cm, poor differentiation, high histological grade, and incomplete resection were significantly associated with recurrence (all P < 0.05). Multivariate analysis confirmed these as independent predictors (all P < 0.01).
conclusionSRF is overexpressed in glioblastoma and closely linked to tumor angiogenesis and postoperative recurrence. High SRF expression may promote tumor progression through vascular remodeling, suggesting its potential utility as a prognostic biomarker and therapeutic target in GBM management.
Indexed as
Identifiers
40753518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.